Cargando…

Safety and adverse reactions in subcutaneous allergen immunotherapy: a review

BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and al...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Cristoforo, Cavaliere, Carlo, Schroeder, Jan W., Leo, Gualtiero, Nicoletta, Francesca, Barone, Alessandro, Ridolo, Erminia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440773/
https://www.ncbi.nlm.nih.gov/pubmed/37539607
http://dx.doi.org/10.23750/abm.v94i4.14239
_version_ 1785093224761655296
author Incorvaia, Cristoforo
Cavaliere, Carlo
Schroeder, Jan W.
Leo, Gualtiero
Nicoletta, Francesca
Barone, Alessandro
Ridolo, Erminia
author_facet Incorvaia, Cristoforo
Cavaliere, Carlo
Schroeder, Jan W.
Leo, Gualtiero
Nicoletta, Francesca
Barone, Alessandro
Ridolo, Erminia
author_sort Incorvaia, Cristoforo
collection PubMed
description BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and also fatalities in the UK and the US, resulting in its limitation and in the introduction of other routes of administration. The aim of this review is to make a reflection about still unclear and unidentified factors favoring severe reactions during SCIT. METHODS: Approaches to prevent fatal or life-threatening reactions to AIT and the current consensus on how to prevent life-threatening reactions to AIT have been taken into account. RESULTS: A decisive advance for SCIT safety was understanding that the major cause of mortality was injecting the allergen extract to patients with uncontrolled asthma. This awareness resulted in a significant decrease in fatalities, but not in their abolition, except for Hymenoptera venom immunotherapy. Among the factors favoring severe reactions there are the administration of a wrong extract or of allergen doses higher than listed, unintentional intravenous administration, and missed dose reduction after protracted interruption. Moreover, in the context of the improving of the safety, the role played in tolerance-promoting by adjuvants such as CpG oligodeoxynucleotides has to be taken into account, as well as the potential preventive effect performed by the monoclonal anti-IgE antibody omalizumab against the exacerbation of severe reactions during SCIT. CONCLUSIONS: The safety of SCIT is good, but the research to improve it further must continue. In particular, the pathophysiological mechanisms related to AIT for inhalants and for Hymenoptera venom should be studied, based on the evident diversity demonstrated by the complete absence of fatal reactions to Hymenoptera venom immunotherapy from its introduction in comparison with the history of serious and fatal offenses examined in this review. (www.actabiomedica.it)
format Online
Article
Text
id pubmed-10440773
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-104407732023-08-22 Safety and adverse reactions in subcutaneous allergen immunotherapy: a review Incorvaia, Cristoforo Cavaliere, Carlo Schroeder, Jan W. Leo, Gualtiero Nicoletta, Francesca Barone, Alessandro Ridolo, Erminia Acta Biomed Review BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and also fatalities in the UK and the US, resulting in its limitation and in the introduction of other routes of administration. The aim of this review is to make a reflection about still unclear and unidentified factors favoring severe reactions during SCIT. METHODS: Approaches to prevent fatal or life-threatening reactions to AIT and the current consensus on how to prevent life-threatening reactions to AIT have been taken into account. RESULTS: A decisive advance for SCIT safety was understanding that the major cause of mortality was injecting the allergen extract to patients with uncontrolled asthma. This awareness resulted in a significant decrease in fatalities, but not in their abolition, except for Hymenoptera venom immunotherapy. Among the factors favoring severe reactions there are the administration of a wrong extract or of allergen doses higher than listed, unintentional intravenous administration, and missed dose reduction after protracted interruption. Moreover, in the context of the improving of the safety, the role played in tolerance-promoting by adjuvants such as CpG oligodeoxynucleotides has to be taken into account, as well as the potential preventive effect performed by the monoclonal anti-IgE antibody omalizumab against the exacerbation of severe reactions during SCIT. CONCLUSIONS: The safety of SCIT is good, but the research to improve it further must continue. In particular, the pathophysiological mechanisms related to AIT for inhalants and for Hymenoptera venom should be studied, based on the evident diversity demonstrated by the complete absence of fatal reactions to Hymenoptera venom immunotherapy from its introduction in comparison with the history of serious and fatal offenses examined in this review. (www.actabiomedica.it) Mattioli 1885 2023 2023-08-03 /pmc/articles/PMC10440773/ /pubmed/37539607 http://dx.doi.org/10.23750/abm.v94i4.14239 Text en Copyright: © 2023 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License
spellingShingle Review
Incorvaia, Cristoforo
Cavaliere, Carlo
Schroeder, Jan W.
Leo, Gualtiero
Nicoletta, Francesca
Barone, Alessandro
Ridolo, Erminia
Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title_full Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title_fullStr Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title_full_unstemmed Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title_short Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
title_sort safety and adverse reactions in subcutaneous allergen immunotherapy: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440773/
https://www.ncbi.nlm.nih.gov/pubmed/37539607
http://dx.doi.org/10.23750/abm.v94i4.14239
work_keys_str_mv AT incorvaiacristoforo safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT cavalierecarlo safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT schroederjanw safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT leogualtiero safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT nicolettafrancesca safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT baronealessandro safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview
AT ridoloerminia safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview